Cover Image
市場調查報告書

全球血液產業

The Global Blood Industry

出版商 BCC Research 商品編碼 180731
出版日期 內容資訊 英文 270 Pages
訂單完成後即時交付
價格
Back to Top
全球血液產業 The Global Blood Industry
出版日期: 2015年03月30日 內容資訊: 英文 270 Pages
簡介

全球血液產品市場,預計從2014年的302億美元以4.9%的年複合成長率推移,2019年達到383億美元的市場規模。各市場區隔中,預計血液治療市場從2014年的約244億美元以5.1%的年複合成長率推移,2019年達到313億美元的市場規模。血型判斷、篩檢產品,預計從2014年的約34億美元以5.4%的年複合成長率推移,2019年達到44億美元的市場規模。

本報告提供全球血液產業現狀與預測相關調查分析、血液產業結構、市場規模的變化與預測、各市場區隔分析與預測、血液利用的模式與趨勢、相關法律、市場企業與相對市場佔有率、目前產品線、新產品與新技術的檢驗、相關專利趨勢等彙整資料,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 概要

  • 血液產業
  • 產業用語
  • 血液產業的歷史
  • 血液與其結構要素
    • 血漿
    • 細胞成分
    • 免疫球蛋白產品
    • 輸血血液的危險性
    • 輸血相關的風險
  • 無病毒的血液供給的配合措施
  • 輸血的負面反應
  • 血液/血漿的結構要素的風險

第4章 血液管理系統-血液的採取、加工、利用

  • 採血
    • 血液機關、血液設施
    • 採血組織
    • 捐血統計
    • 美國的統計
    • 歐洲的統計
    • 亞太地區的統計
    • 捐贈者募集、規定
    • 血液篩檢、評估
    • 從捐贈者採血液的方法
    • 血漿採取
    • 血型判斷及病診斷檢驗
    • 血液加工
    • 輸血
    • 輸血的種類
  • 血液管理的問題

第5章 血液商務的法規

  • 美國的血液產業相關的法規

第6章 全球血液、血液產品市場概要

  • 產業的促進要素
  • 市場摘要
    • 血液的價格
    • 輸血治療的模式

第7章 血液產業分析

  • 全球全血採取市場
    • 各國的配合措施、改善點
    • 美國的血液採取資料
  • 全球原料血漿採取市場
  • 全球血液治療市場
    • 血漿、血漿來源的產品
    • 白蛋白、血漿蛋白質的比例(PPF)
    • 凝血因子
    • 免疫球蛋白
    • 免疫球蛋白市場規模
    • 纖維蛋白膠和凝血酶
    • 抗凝血酵素III
  • 全球血型判斷、篩檢產品
  • 血液檢驗
    • 聚合酵素鏈鎖反應(PCR)放大
    • 核酸增幅檢查(NAT)
    • 免疫檢測法
  • 捐贈者篩檢用血液檢驗產品的市場規模
  • 血型判斷
    • 市場結構、參與企業
    • 市場規模
  • 全球血液加工設備、相關產品市場
    • 採取用產品
    • 血液、血漿採取用品
    • 血漿、血液採取設備
    • 市場參與企業
    • 輸血用產品

第8章 血液的研究開發

  • 血液專門研究機關
    • JEROME H. HOLLAND LABORATORY (ARC)
    • NATIONAL BLOOD FOUNDATION (NBF)
  • 幹細胞研究
  • 替代血液
  • 基因重組的開發趨勢
  • 免疫球蛋白的新開發
  • 纖維蛋白膠、黏劑
  • 老年癡呆症用白蛋白、免疫球蛋白靜脈注射治療
  • 提高血液供給安全性的臨床實驗用醫療設備
  • 獸醫療用血液的市場

第9章 技術

  • 傳統的分餾法
    • COHN分餾法
  • 最新的分餾法
  • 放大法
    • 聚合酵素鏈鎖反應(PCR)
    • 核酸擴增技術(NAT)
  • 免疫檢測法
    • 酵素免疫分析法
  • 專利分析
  • 專利案例

第10章 FDA的認證機關

第11章 企業簡介

第12章 附錄:主要的資訊來源

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HLC008J

Global sales of blood products grew to nearly $30.2 billion in 2014 from $28.7 billion in 2013. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 4.9% from 2014 to 2019, totaling nearly $38.3 billion in 2019.

This report provides:

  • An overview of the structure and current market size of the global blood industry, including coverage of such segments as blood and plasma collection, blood and plasma processing, blood therapeutic products, plasma therapeutic products, and emerging trends and products.
  • Analyses of global market trends, with data from 2011 to 2014, and projections of CAGRs through 2019.
  • Government and regulatory controls.
  • The impact of diseases on the blood industry.
  • Comprehensive company profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE AND FORMAT

This study encompasses the wide range of products and services that comprise the global blood industry marketplace. The U.S. market, the largest in the world, provides the primary market breakdown with supplemental information given for other regions. The focus of the report is two-fold: first, blood for donation and the components and derived products from this blood and plasma, and second, products used to provide and support collection, processing and transfusion. Excluded from consideration are the clinical blood tests for diseases and conditions not involved in managing blood and plasma products.

ANALYST'S CREDENTIALS

Melissa Elder is an experienced healthcare market analyst, specializing in prescription and over-the-counter pharmaceuticals, medical devices and emerging healthcare technologies. Ms. Elder has more than 20 years of experience in the healthcare industry, specializing in market research for the past 16 years. This experience has given her substantial insight into pharmaceutical and medical device market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOAL AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE AND FORMAT
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • OVERVIEW
  • MAJOR FINDINGS
  • SUMMARY TABLE GLOBAL SALES OF BLOOD PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL SALES OF BLOOD PRODUCTS, 2011-2019 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • THE BLOOD INDUSTRY
  • BLOOD INDUSTRY TERMS AND ABBREVIATIONS[1]
  • HISTORY OF THE BLOOD INDUSTRY
  • TABLE 1 TIMELINE OF THE BLOOD INDUSTRY
  • BLOOD AND ITS COMPONENTS
  • TABLE 2 COMPOSITION OF BLOOD 1
    • PLASMA 1
    • CELLULAR ELEMENTS 1
      • Red and White Blood Cells
      • Platelets
    • IMMUNOGLOBULIN PRODUCTS
    • THE DANGERS OF TRANSFUSED BLOOD
    • RISKS ASSOCIATED WITH TRANSFUSION
      • National Healthcare Safety Network -Biovigilance Component Hemovigilance Module Surveillance
      • Diseases Contracted from Blood Transfusions and Related Identification Testing
      • TABLE 3 MAJOR DISEASES CONTRACTED FROM BLOOD TRANSFUSIONS, U.S. ANALYSIS
        • HIV/AIDS
        • TABLE 4 CBER LICENSED HIV DONOR SCREENING TESTS (LAST UPDATED JULY 2014)
        • Hepatitis A
        • Hepatitis B
        • TABLE 5 CBER-LICENSED SCREENING TESTS FOR HEPATITIS B (LAST UPDATED JULY 2014)
        • Hepatitis C
        • TABLE 6 CBER-LICENSED SCREENING TESTS FOR HEPATITIS C (LAST UPDATED JULY 2014)
        • Hepatitis D
        • Hepatitis E
        • Human T-Cell Lymphotropic Virus-(HTLV-I, -II)
        • TABLE 7 CBER-LICENSED SCREENING TESTS FOR HTLV-I AND HTLV-II (LAST UPDATED JULY 2014)
        • Cytomegalovirus
        • TABLE 8 CBER-LICENSED SCREENING TESTS FOR CMV (LAST UPDATED JULY 2014)
        • West Nile Virus
        • TABLE 9 CBER LICENSED SCREENING TESTS FOR WEST NILE (LAST UPDATED JULY 2014)
        • "Mad Cow Disease"-Creutzfeldt-Jakob Disease (CJD)
        • Syphilis
        • Advances in Rapid Syphilis Detection
        • TABLE 10 CBER-APPROVED MANUFACTURERS FOR SYPHILIS TESTS (LAST UPDATED JULY 2014)
        • Chagas Disease
        • TABLE 11 CBER-LICENSED SCREENING TESTS FOR T. CRUZI (LAST UPDATED JULY 2014)
        • Chlamydia Trachomatis
        • TABLE 12 CBER-APPROVED MANUFACTURERS FOR CHLAMYDIA SCREENING TESTS (LAST UPDATED JULY 2014)
        • Neisseria Gonorrhea
        • TABLE 13 CBER-LICENSED SCREENING TESTS FOR GONORRHEA (LAST UPDATED JULY 2014)
    • EFFORTS TO CREATE A VIRUS-FREE BLOOD SUPPLY
      • Plasma Treatments
        • Trinitrobutyl Phosphate and Sodium Cholate
        • Methylene Blue-treated Plasma
      • Amatosalen HCL-Treated Plasma
      • Platelet Treatments
      • RBCs
    • NEGATIVE REACTIONS FROM BLOOD TRANSFUSIONS
    • BLOOD/PLASMA COMPONENT RISKS

CHAPTER 4 THE BLOOD MANAGEMENT SYSTEM: BLOOD COLLECTION, PROCESSING AND USE

  • BLOOD COLLECTION
    • TYPES OF BLOOD ESTABLISHMENTS AND BLOOD FACILITIES
      • Major Facilities
      • Auxiliary Facilities
      • Transfusion Services
    • ORGANIZATIONS COLLECTING BLOOD
    • TABLE 14 FDA-REGISTERED BLOOD ESTABLISHMENTS BY STATE' AND POSSESSION
      • For-Profit Blood Collection
      • Plasma Collection Centers
        • National Donor Deferral Registry
      • Nonprofit Blood Collection 4
        • American Red Cross
        • Community Blood Banks
        • Hospitals
        • Additional Blood Collection Sites
    • BLOOD DONATION DEMOGRAPHICS
      • Global Demographic Trends
      • TABLE 15 ESTIMATED WORLD POPULATION ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
      • FIGURE 1 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
      • TABLE 16 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
      • FIGURE 2 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
    • U.S. DEMOGRAPHICS
    • TABLE 17 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
    • FIGURE 3 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
      • Gender, Age and Life Expectancy
      • TABLE 18 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY GENDER, 2000 AND 2020 (YEARS)
      • FIGURE 4 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY GENDER, 2000-2020 (YEARS)
    • EUROPEAN DEMOGRAPHICS
    • TABLE 19 EUROPE POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
    • FIGURE 5 EUROPE POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
    • ASIA-PACIFIC DEMOGRAPHICS
    • TABLE 20 ASIA-PACIFIC POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
    • FIGURE 6 ASIA-PACIFIC POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
      • Global Life Expectancy
      • TABLE 21 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013 (YEARS)
      • FIGURE 7 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013 (YEARS)
    • DONOR RECRUITMENT AND REGULATIONS
    • BLOOD SCREENING AND EVALUATION
    • METHODS FOR COLLECTING BLOOD FROM A DONOR
      • Manual Collection
      • Automated Collection
        • Plasmapheresis
        • Plateletpheresis
        • Leukopheresis
        • Red Blood Cell Apheresis
    • PLASMA COLLECTION
      • Commercial Nature of Plasmapheresis
      • Global Nature of the Plasma Industry
      • Plasma Fractionators
      • Distributors/Brokers
    • BLOOD TYPING AND TESTING FOR DISEASES
      • Blood Typing 6
      • TABLE 22 TESTS ROUTINELY PERFORMED ON BLOOD DONATIONS
      • TABLE 23 BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS
      • Methods of Typing
        • Manual Blood Typing Methods
          • Slide/Tile Testing
          • Tube Testing
          • Microplate
        • Automated Blood Typing and Screening Methods
      • Blood Testing
      • Blood Storage
    • BLOOD PROCESSING
      • Preparation and Use of the Components
        • Red Blood Cell Components
        • Platelets
        • Plasma
    • BLOOD TRANSFUSIONS
      • Transfusion in the U.S.
      • Testing before Transfusion
        • Manual Crossmatch Techniques
          • Major Crossmatch
          • Minor Crossmatch
          • Antibody Screen
          • Coombs Test
    • TYPES OF TRANSFUSIONS
      • Whole Blood
      • Packed Red Blood Cells
      • Platelets
      • Leukocytes
      • Fresh Frozen Plasma (FFP)
      • TABLE 24 SELECTED USES OF FFP
      • Cryoprecipitate
      • Coagulation Factors
      • TABLE 25 LISTING OF BLOOD PRODUCTS FOR THERAPEUTIC USE
      • Immune Serum Globulin/IMIG/IGIV
      • Factor VIII
      • Factor IX and Factor IX Complex
      • Factor VIIa
      • Fibrin/Thrombin
      • Therapeutic Apheresis
      • Experimental Blood and Plasma Products
  • BLOOD MANAGEMENT ISSUES
    • AVAILABILITY ISSUES
    • BLOODLESS SURGERY
      • Bloodless Medicine and Surgery Hospital Directory
    • SAFETY ISSUES: RISK MANAGEMENT
    • TABLE 26 FACTORS TO REDUCE RISKS OF TRANSFUSION-ASSOCIATED DISEASES
      • Better Donor Screening
      • Better Viral Screening Tests
      • Get More Repeat Donors
      • Develop Better Viral Inactivation Processes
      • Selective Use of Blood Derivative Products
    • BLOOD TRANSFUSION FATALITIES
    • TABLE 27 TRANSFUSION-RELATED FATALITIES BY COMPLICATION, FY2008 -FY2012
    • TABLE 28 FATALITIES NOT RELATED TO TRANSFUSION OR TRANSFUSION NOT RULED OUT, FY2008-FY2012
    • TABLE 29 POST-DONATION "NOT RULED OUT" FATALITY REPORTS BY DONATED PRODUCT, FY2008-FY2012

CHAPTER 5 REGULATION OF THE BLOOD BUSINESS

  • REGULATION OF THE U.S. BLOOD BUSINESS
  • TABLE 30 FEDERAL ORGANIZATIONS RESPONSIBLE FOR U.S. BLOOD SAFETY
    • STATUTORY AUTHORITY OF THE FDA
      • Center for Biologics Evaluation and Research
        • Office of Regulatory Affairs (ORA)
        • Office of Biologics, the Division of Blood and Blood Products
        • TABLE 31 FDA AUTHORITY IN REGULATING BLOOD BANKING AND BLOOD PRODUCTS
    • THE MAJOR REGULATIONS AND POLICY MATTERS CONCERNING THE U.S. BLOOD SUPPLY
      • The Clinical Laboratory Improvement Act of 1988 (CLIA)
      • The FDA'S Five Layers
        • Donor Screening
        • Blood Testing
        • Donor Deferral Lists
        • Quarantine
        • Problems and Deficiencies
      • The FDA Blood Action Plan
      • Team Biologics
        • Program Alignment Action Plan for Fiscal 2015
      • Fuel, Phone Excise Taxes
    • HOW REGULATIONS ARE IMPLEMENTED 9
      • Inspecting Blood Banks and Plasma Collection Facilities
      • TABLE 32 MAJOR AREAS OF CONCERN FOR INSPECTING BLOOD FACILITIES 9
    • GUIDANCE FOR INDUSTRY RECOGNITION AND USE OF A STANDARD FOR THE UNIFORM LABELING OF BLOOD AND BLOOD COMPONENTS
    • OTHER ORGANIZATIONS INVOLVED IN BLOOD REGULATION
      • National Heart, Lung and Blood Institute (NHLBI)
        • Blood Diseases and Resources Program
      • Health Care Financing Administration (HCFA)
      • The Department of Defense
      • State Regulatory Agencies
    • VOLUNTARY REGULATION BY PROFESSIONAL AND TRADE ASSOCIATIONS
      • PPTA: Plasma Protein Therapeutics Association
      • America's Blood Centers (ABC)
    • THE EUROPEAN UNION (EU) BLOOD DIRECTIVE
      • The International Society for Blood Transfusion - ISBT 128

CHAPTER 6 THE GLOBAL BLOOD AND BLOOD PRODUCTS MARKET OVERVIEW

  • DRIVING FORCES OF THE INDUSTRY
  • FIGURE 8 VARIABLES INFLUENCING THE DYNAMICS OF DEMAND FOR BLOOD FOR TRANSFUSION
  • MARKET SUMMARY
  • FIGURE 9 BLOOD MARKET COST AND PRICING ANALYSIS
    • PRICING OF BLOOD
    • TABLE 33 U.S. COST OF BLOOD COMPONENTS, ESTIMATED, THROUGH 2014 ($)
      • National Blood Exchange (NBE)
      • RBCs and Leukoreduced RBCs
      • Platelets
      • Random Donor Platelets
      • Fresh Frozen Plasma (FFP)
      • Cryoprecipitate
      • Washed Cells
      • Deglycerolized Cells
      • Granulocytes
      • Gamma-Irradiated Blood
    • PATTERNS OF TRANSFUSION PROCEDURES
      • Leukoreduction
      • Impact of Autologous Donations
        • Types of Autologous Transfusions
        • Risks of PABD
      • Procedure Codes for Blood Transfusions and Related Services
      • TABLE 34 U.S. BLOOD TRANSFUSION AND RELATED SERVICES CODES

CHAPTER 7 BLOOD INDUSTRY ANALYSIS

  • GLOBAL MARKETS FOR WHOLE BLOOD COLLECTIONS
    • LOCAL EFFORTS AND IMPROVEMENTS
      • Africa
        • South Africa
      • Asia
        • China
        • India
        • Japan
        • Pakistan
        • Islamic Republic of Iran
        • Sri Lanka
        • Vietnam
      • Europe
        • Britain
        • France
        • Germany
        • Russia
        • Montenegro
        • Netherlands
        • Switzerland
        • Turkey
      • North America and Caribbean
        • Canada
        • Haiti
      • Oceana Region
        • Australia
        • New Zealand
        • Cook Islands
      • South America
        • Argentina
        • Bolivia
        • Brazil
    • U.S. BLOOD COLLECTION DATA
    • TABLE 35 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, THROUGH 2019* (MILLION UNITS/PINTS)
    • FIGURE 10 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, 2007-2019 (MILLION UNITS/PINTS)
  • GLOBAL MARKETS FOR SOURCE PLASMA COLLECTIONS
  • TABLE 36 ESTIMATED AND PROJECTED GLOBAL PLASMA COLLECTIONS AND VALUES, THROUGH 2019 ($ BILLIONS, MILLIONS ML)
  • FIGURE 11 ESTIMATED AND PROJECTED GLOBAL PLASMA COLLECTIONS MARKET VALUE, 2013-2019 ($ BILLIONS)
  • GLOBAL MARKETS FOR BLOOD THERAPEUTICS
  • TABLE 37 GLOBAL SALES OF PLASMA THERAPEUTICS*, THROUGH 2019 ($ MILLIONS)
  • FIGURE 12 GLOBAL SALES OF PLASMA THERAPEUTICS*, 2011-2019 ($ MILLIONS)
  • FIGURE 13 MARKET SHARE FOR PLASMA THERAPEUTIC SALES BY REGION, 2014 (%)
    • PLASMA AND PLASMA-DERIVED PRODUCTS
      • Plasma Therapeutic Products
      • TABLE 38 GLOBAL MARKET SIZE PLASMA THERAPEUTIC DERIVATIVES BY TYPE, THROUGH 2019 ($ MILLIONS)
      • FIGURE 14 GLOBAL MARKET SIZE PLASMA THERAPEUTIC DERIVATIVES BY TYPE, 2011-2019 ($ MILLIONS)
    • ALBUMIN AND PLASMA PROTEIN FRACTION (PPF)
      • Recombinant Human Albumin
      • Albumin Market Dynamics
      • TABLE 39 ALBUMIN AND PLASMA PROTEIN FRACTION (PPF) PRODUCTS (%)
      • Albumin and PPF Market Size
      • TABLE 40 GLOBAL MARKET FOR ALBUMIN AND PPF, THROUGH 2019 ($ MILLIONS)
      • FIGURE 15 GLOBAL MARKET FOR ALBUMIN AND PPF, 2011-2019 ($ MILLIONS)
      • TABLE 41 GLOBAL MARKET FOR ALBUMIN AND PPF BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 16 GLOBAL MARKET FOR ALBUMIN AND PPF BY REGION, 2011-2019 ($ MILLIONS)
      • Albumin and PPF Market Trends
    • CLOTTING FACTORS
    • TABLE 42 EXAMPLES OF COMMON BLOOD CLOTTING FACTORS
      • Hemophilia
      • TABLE 43 GLOBAL AND U.S. HEMOPHILIA STATISTICS
      • Market Demand and Market Size
      • TABLE 44 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, THROUGH 2019 ($ MILLIONS)
      • FIGURE 17 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, 2011-2019 ($ MILLIONS)
      • FIGURE 18 GLOBAL MARKET SHARE OF CLOTTING FACTOR SALES BY HUMAN AND RECOMBINANT PRODUCTS, 2014 (%)
      • TABLE 45 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 19 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS BY REGION, 2011-2019 ($ MILLIONS)
      • Factor VIII
      • TABLE 46 APPROVED FACTOR VIII PRODUCTS
      • TABLE 47 GLOBAL MARKET SHARE FACTOR VIII COMPANIES, 2014 (%/$ MILLIONS)
      • FIGURE 20 GLOBAL MARKET SHARE OF FACTOR VIII COMPANIES, 2014 (%)
      • FIGURE 21 GLOBAL MARKET SHARE OF FACTOR VIII SALES BY HUMAN AND RECOMBINANT PRODUCTS, 2014 (%)
      • Factor IX
      • TABLE 48 APPROVED FACTOR IX PRODUCTS
      • TABLE 49 GLOBAL MARKET SHARE FACTOR IX COMPANIES, 2014 (%/$ MILLIONS)
      • FIGURE 22 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2014 (%)
      • FIGURE 23 GLOBAL MARKET SHARE OF FACTOR IX SALES BY HUMAN AND RECOMBINANT PRODUCTS, 2014 (%)
      • Factor VIIa
      • Biosimilar Factor VIIa Development
      • TABLE 50 APPROVED FACTOR VII PRODUCTS
      • TABLE 51 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2014 (%/$ MILLIONS)
      • FIGURE 24 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2014 (%)
      • Factor XIII
      • TABLE 52 APPROVED FACTOR XIII PRODUCTS
      • Prothrombin Complex Concentrates
      • TABLE 53 APPROVED PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS
    • IMMUNOGLOBULINS
      • IVIG
      • TABLE 54 SELECTED CONDITIONS TREATED BY IVIG
      • TABLE 55 APPROVED IMMUNOGLOBULINS
      • Hyperimmunes
      • TABLE 56 APPROVED HYPERIMMUNE IMMUNOGLOBULINS
      • Other
        • IMIG
    • IMMUNOGLOBULIN MARKET SIZE
    • TABLE 57 GLOBAL MARKET FOR IMMUNOGLOBULINS, THROUGH 2019 ($ MILLIONS)
    • FIGURE 25 GLOBAL MARKET FOR IMMUNOGLOBULINS, 2011-2019 ($ MILLIONS)
    • TABLE 58 GLOBAL MARKET FOR IMMUNOGLOBULINS BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 26 GLOBAL MARKET FOR IMMUNOGLOBULINS BY REGION, 2011-2019 ($ MILLIONS)
      • Respiratory Syncytial Virus
      • Hepatitis B Immune Globulin
      • Alpha-1-Proteinase Inhibitor
      • Other Immunoglobulin Segments
        • CMV Immunoglobulin
        • Rabies Immunoglobulin
        • Rho(D) Immunoglobulin
        • Tetanus Immunoglobulin (TIG)
        • Vaccinia Immune Globulin Intravenous (VIG)
        • Varicella Immunoglobulin
        • TABLE 59 GLOBAL MARKET SHARE OF IMMUNOGLOBULIN COMPANIES, 2014
        • FIGURE 27 GLOBAL MARKET SHARE OF IMMUNOGLOBULIN COMPANIES, 2014 (%)
    • FIBRIN SEALANTS AND THROMBIN
    • TABLE 60 APPROVED FIBRIN SEALANTS AND FIBRIN PRODUCTS
      • Fibrin Sealants and Thrombin Market Size
      • TABLE 61 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN, THROUGH 2019 ($ MILLIONS)
      • FIGURE 28 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN, 2011- 2019 ($ MILLIONS)
      • TABLE 62 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 29 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN BY REGION, 2011-2019 ($ MILLIONS)
      • TABLE 63 GLOBAL MARKET SHARE OF FIBRIN SEALANTS AND THROMBIN PRODUCT COMPANIES, 2014 (%/$ MILLIONS)
      • FIGURE 30 GLOBAL MARKET SHARE OF FIBRIN SEALANTS AND THROMBIN PRODUCT COMPANIES, 2014 (%)
    • ANTITHROMBIN III
    • TABLE 64 APPROVED ANTITHROMBIN PRODUCTS
      • Antithrombin Market Size
      • TABLE 65 GLOBAL MARKET FOR ANTITHROMBIN, THROUGH 2019 ($ MILLIONS)
      • FIGURE 31 GLOBAL MARKET FOR ANTITHROMBIN, 2011-2019 ($ MILLIONS)
      • TABLE 66 GLOBAL MARKET FOR ANTITHROMBIN BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 32 GLOBAL MARKET FOR ANTITHROMBIN BY REGION, 2011-2019 ($ MILLIONS)
  • GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS
  • TABLE 67 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS BY REGION, THROUGH 2019 ($ MILLIONS)
  • FIGURE 33 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS BY REGION, 2011-2019 ($ MILLIONS)
  • FIGURE 34 MARKET SHARE FOR BLOOD TYPING AND SCREENING PRODUCT SALES BY REGION, 2014 (%)
  • TABLE 68 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • FIGURE 35 GLOBAL MARKET FOR BLOOD TYPING AND SCREENING PRODUCTS, 2011-2019 ($ MILLIONS)
    • SCREENING BLOOD
    • POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION
    • TABLE 69 SELECTED PCR DONOR SCREENING TESTS
    • NUCLEIC ACID AMPLIFICATION TEST (NAAT)
    • TABLE 70 SELECTED NAT DONOR SCREENING TESTS
    • IMMUNOASSAY
    • TABLE 71 SELECTED IMMUNOASSAY DONOR SCREENING TESTS
  • MARKET SIZE OF BLOOD TESTING PRODUCTS FOR DONOR SCREENING
  • TABLE 72 GLOBAL BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TESTS, THROUGH 2019 ($ MILLIONS)
  • FIGURE 36 GLOBAL BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TEST, 2011- 2019 ($ MILLIONS)
  • BLOOD TYPING
  • TABLE 73 BLOOD GROUP AND RH TYPE AND COMPATIBLE BLOOD FOR TRANSFUSION
    • MARKET STRUCTURE AND PARTICIPANTS
      • Manual Typing Methods
      • Automated Blood Typing
        • Beckman Coulter
        • Immucor
        • Ortho Clinical Diagnostics
    • MARKET SIZE OF BLOOD TYPING
    • TABLE 74 GLOBAL BLOOD TYPING MARKET: INSTRUMENTS AND SUPPLIES BY TYPE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 37 GLOBAL BLOOD TYPING MARKET: INSTRUMENTS AND SUPPLIES BY TYPE, 2011-2019 ($ MILLIONS)
  • GLOBAL MARKETS FOR BLOOD PROCESSING EQUIPMENT AND ASSOCIATED PRODUCTS
  • TABLE 75 GLOBAL SALES OF BLOOD COLLECTION AND PROCESSING EQUIPMENT AND DISPOSABLES, THROUGH 2019 ($ MILLIONS)
  • FIGURE 38 GLOBAL SALES OF BLOOD COLLECTION AND PROCESSING EQUIPMENT AND DISPOSABLES, 2011-2019 ($ MILLIONS)
  • FIGURE 39 MARKET SHARE FOR BLOOD COLLECTION AND PROCESSING EQUIPMENT AND DISPOSABLE SALES BY REGION, 2014 (%)
  • TABLE 76 GLOBAL MARKET FOR BLOOD AND PLASMA COLLECTION/ TRANSFUSION PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • FIGURE 40 GLOBAL MARKET FOR BLOOD AND PLASMA COLLECTION/ TRANSFUSION PRODUCTS, 2011-2019 ($ MILLIONS)
    • COLLECTION PRODUCTS
    • TABLE 77 GLOBAL MARKET FOR BLOOD COLLECTION PRODUCTS BY TYPE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 41 GLOBAL MARKET FOR COLLECTION PRODUCTS BY TYPE, 2011-2019 ($ MILLIONS)
    • BLOOD AND PLASMA COLLECTION SUPPLIES
      • Plasma Collection Sets
      • Blood Bags
    • PLASMA AND BLOOD COLLECTION EQUIPMENT
      • Blood Salvage
      • Other Collection Equipment
    • MARKET PARTICIPANTS
      • Haemonetics
        • PCS2
        • Cymbal
        • MCS+ 8150 System
        • MCS+ 9000 System
        • Cell Saver Systems
        • OrthoPAT System
        • ACP 215 System
      • Fresenius Kabi (Fenwal Inc.)
        • Apheresis Collections
          • Autopheresis-C
          • Alyx Component Collection System
          • Amicus Separator
          • Aurora
        • Terumo BCT
    • TRANSFUSION PRODUCTS
    • TABLE 78 GLOBAL MARKET FOR TRANSFUSION PRODUCTS BY TYPE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 42 GLOBAL MARKET FOR TRANSFUSION PRODUCTS BY TYPE, 2011-2019 ($ MILLIONS)
      • Transfusion Sets
      • Blood Filter Market
      • Transfusion Equipment
      • Accessories

CHAPTER 8 BLOOD RESEARCH AND DEVELOPMENT

  • DEDICATED BLOOD RESEARCH FACILITIES
    • JEROME H. HOLLAND LABORATORY (ARC)
    • NATIONAL BLOOD FOUNDATION (NBF)
  • STEM CELL RESEARCH
  • BLOOD SUBSTITUTES
  • RECOMBINANT DEVELOPMENT ACTIVITIES
  • NEW DEVELOPMENTS IN IMMUNOGLOBULINS
  • CSL BEHRING'S COMMITMENT TO CLOTTING FACTOR DEVELOPMENT
  • FIBRIN SEALANT AND GLUE DEVELOPMENTS
  • ALBUMIN AND IVIG TREATMENT FOR ALZHEIMER'S DISEASE
  • TABLE 79 CLINICAL TRIAL: ALBUMIN IN ALZHEIMER'S TREATMENT
  • INVESTIGATIONAL DEVICE TO HELP IMPROVE BLOOD SUPPLY SAFETY
  • THE VETERINARY BLOOD MARKET
  • TABLE 80 DOG AND CAT BLOOD TYPES AND DESCRIPTIONS
  • TABLE 81 REGIONAL VETERINARY BLOOD BANKS

CHAPTER 9 TECHNOLOGY

  • CLASSICAL FRACTIONATION METHODS
    • COHN FRACTIONATION
  • ADVANCED FRACTIONATION METHODS
  • AMPLIFICATION METHODS
    • POLYMERASE CHAIN REACTION (PCR)
    • NUCLEIC ACID AMPLIFICATION TECHNOLOGY (NAT)
  • IMMUNOASSAY
    • ENZYME IMMUNOASSAY (EIA)
      • Basic EIA
      • FIGURE 43 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS
      • Alternate EIA Methods
        • Second-Antibody Precipitation Method
        • Double-Antibody Sandwich Method
        • Reverse-Sandwich Method
        • Reverse-Sandwich Inhibition Method
  • PATENT ANALYSIS
  • TABLE 82 RECENTLY ISSUED PATENTS
  • TABLE 83 PATENTS BY COUNTRY OF ORIGIN
  • TABLE 84 RECENT PATENTS BY ASSIGNEE
    • FRESENIUS MEDICAL CARE
    • ORTHO-CLINICAL DIAGNOSTICS INC.
    • ABBOTT LABORATORIES
    • ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    • AUBURN UNIVERSITY
    • CERNER INNOVATION INC.
    • CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES
    • FENWAL INC.
    • GELANUS B.V.
    • MICRONICS INC.
    • NEW YORK BLOOD CENTER INC.
    • TERUMO KABUSHIKI KAISHA
  • PATENT EXAMPLES
    • RECENT PATENTS
      • Blood Transfusions: Six Patents
      • Blood Bank: Three Patents
      • Blood Donor: Three Patents

CHAPTER 10 FDA LICENSED BLOOD ESTABLISHMENTS

  • GUIDANCE FOR INDUSTRY RECOGNITION AND USE OF A STANDARD FOR THE UNIFORM LABELING OF BLOOD AND BLOOD COMPONENTS
    • LABELING STANDARDS
    • REPORTING REQUIREMENTS FOR LICENSED ESTABLISHMENTS
    • FDA-LICENSED ESTABLISHMENTS

CHAPTER 11 COMPANY PROFILES

  • ABBOTT LABORATORIES
  • TABLE 85 ABBOTT'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 44 ABBOTT'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • ASTRAZENECA PLC
  • TABLE 86 ASTRAZENECA'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 45 ASTRAZENECA'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • BAXTER INTERNATIONAL INC.
  • TABLE 87 BAXTER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 46 BAXTER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • BAYER AG
  • TABLE 88 BAYER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 47 BAYER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • BIO-RAD LABORATORIES INC.
  • TABLE 89 BIO-RAD'S SALES HISTORY, 2012-2014* ($ THOUSANDS)
  • FIGURE 48 BIO-RAD'S SALES HISTORY, 2012-2014* ($ THOUSANDS)
  • CSL BEHRING
  • TABLE 90 CSL LIMITED'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 49 CSL LIMITED'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • ENTEGRION INC.
  • GRIFOLS INTERNATIONAL, S.A./TALECRIS
  • TABLE 91 GRIFOLS' SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 50 GRIFOLS' SALES HISTORY, 2012-2014* ($ MILLIONS)
  • HAEMONETICS CORP.
  • TABLE 92 HAEMONETICS' SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 51 HAEMONETICS' SALES HISTORY, 2012-2014* ($ MILLIONS)
  • HOLOGIC INC.
  • TABLE 93 HOLOGIC'S SALES HISTORY, 2012-2014 ($ MILLIONS)
  • FIGURE 52 HOLOGIC'S SALES HISTORY, 2012-2014 ($ MILLIONS)
  • LFB GROUP
  • TABLE 94 LFB GROUP'S SALES HISTORY, 2012-2013 ($ MILLIONS)
  • FIGURE 53 LFB GROUP'S SALES HISTORY, 2012-2013 ($ MILLIONS)
  • NOVO NORDISK A/S
  • TABLE 95 NOVO NORDISK'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 54 NOVO NORDISK'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • OCTAPHARMA AG
  • TABLE 96 OCTAPHARMA'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 55 OCTAPHARMA'S SALES HISTORY 2012-2014* ($ MILLIONS)
  • PFIZER INC.
  • TABLE 97 PFIZER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 56 PFIZER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • ROCHE HOLDING LTD.
  • TABLE 98 ROCHE'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 57 ROCHE'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • SANOFI S/A
  • TABLE 99 SANOFI'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 58 SANOFI'S SALES HISTORY, 2012-2014* ($ MILLIONS)

CHAPTER 12 APPENDIX: MAJOR SOURCES OF INFORMATION

  • COMPANIES
    • ABAXIS INC.
    • ABBOTT LABORATORIES
    • ALBUMIN BIOSCIENCE
    • ALERE INC.
    • ALFA SCIENTIFIC DESIGNS INC.
    • AMERICAN RED CROSS
    • ARKRAY INC.
    • ARYOGEN BIOPHARMA CO.
    • ASTRAZENECA PLC
    • AVIOQ INC.
    • BAXTER INTERNATIONAL INC.
    • BAYER AG
    • BECKMAN COULTER INC.
    • BECTON, DICKINSON, & CO.
    • BIOGEN IDEC
    • BIOMERIEUX FRANCE
    • BIO PRODUCTS LABORATORY LTD.
    • BIO-RAD LABORATORIES INC.
    • BIOTEST AG
    • BRISTOL-MYERS SQUIBB CO.
    • BTG INTERNATIONAL
    • BTNX INC.
    • CANGENE CORP. (SEE EMERGENT BIOSOLUTIONS)
    • CHARTER MEDICAL LTD.
    • CHURCH & DWIGHT CO. INC.
    • CSL BEHRING
    • DANAHER CORP.
    • EMERGENT BIOSOLUTIONS
    • ENTEGRION INC.
    • FORA CARE INC.
    • FRESENIUS KABI AG
    • FUJIREBIO DIAGNOSTICS INC.
    • GAMBRO INC.
    • G.E. HEALTHCARE LTD.
    • GLAXOSMITHKLINE PLC
    • GRIFOLS INTERNATIONAL, S.A.
    • HAEMONETICS CORP.
    • HAEMOTRONIC S.P.A.
    • HEMACARE CORP.
    • HEMOCUE AB
    • HOLOGIC INC.
    • IMMUCOR INC.
    • INTERNATIONAL TECHNIDYNE CORP.
    • JANT PHARMACAL CORP.
    • JOHNSON & JOHNSON
    • KEDRION S.P.A
    • LFB GROUP
    • MERIDIAN BIOSCIENCE INC.
    • NATIONAL GENETICS INSTITUTE
    • NEXTRON MEDICAL TECHNOLOGIES
    • NIPRO DIAGNOSTICS INC.
    • NOVA BIOMEDICAL CORP.
    • NOVARTIS AG
    • NOVO NORDISK A/S
    • NOVOZYMES BIOPHARMA DK A/S
    • OCTAPHARMA AG
    • OMRIX BIOPHARMACEUTICALS LTD. (SEE JOHNSON & JOHNSON)
    • ORASURE TECHNOLOGIES INC.
    • ORTHO CLINICAL DIAGNOSTICS INC.
    • PALL CORP.
    • PFIZER INC.
    • PHAMATECH INC.
    • PRINCETON BIOMEDITECH CORP.
    • QIAGEN N.V.
    • QUEST DIAGNOSTICS
    • QUIDEL CORP.
    • RESPONSE BIOMEDICAL CORP.
    • REVO BIOLOGICS
    • ROCHE HOLDING LTD.
    • SANOFI S/A
    • SANQUIN BLOOD SUPPLY
    • SA SCIENTIFIC LTD.
    • SEKISUI DIAGNOSTICS
    • SIEMENS MEDICAL SOLUTIONS
    • SPECTRAL DIAGNOSTICS
    • STANBIO LABORATORY
    • TAKEDA PHARMACEUTICAL CO. LTD.
    • TERUMO BCT
    • TRINITY BIOTECH PLC
    • ZEUS SCIENTIFIC INC.
  • GLOBAL BLOOD DONATION SOURCES
    • AMERICAN ASSOCIATION OF BLOOD BANKS
    • AMERICAN FRIENDS OF MAGEN DAVID ADOM
    • ARMED SERVICES BLOOD PROGRAM
    • ASSOCIATION OF VOLUNTARY ITALIAN BLOOD DONORS
    • AUSTRALIAN RED CROSS
    • CANADIAN BLOOD SERVICES
    • HEARTLAND BLOOD CENTERS
    • HONG KONG RED CROSS
    • INDIAN RED CROSS SOCIETY
    • IRISH NATIONAL BLOOD CENTRE
    • JAPANESE RED CROSS SOCIETY
    • NATIONAL BLOOD SERVICE
    • NEW ZEALAND BLOOD SERVICE
    • SOUTH AFRICAN NATIONAL BLOOD SERVICE
    • WORLD HEALTH ORGANIZATION

LIST OF TABLES

  • SUMMARY TABLE GLOBAL SALES OF BLOOD PRODUCTS, THROUGH 2019 ($ MILLIONS) 8 TABLE 1 TIMELINE OF THE BLOOD INDUSTRY
  • TABLE 2 COMPOSITION OF BLOOD
  • TABLE 3 MAJOR DISEASES CONTRACTED FROM BLOOD TRANSFUSIONS, U.S. ANALYSIS
  • TABLE 4 CBER LICENSED HIV DONOR SCREENING TESTS (LAST UPDATED JULY 2014)
  • TABLE 5 CBER-LICENSED SCREENING TESTS FOR HEPATITIS B (LAST UPDATED JULY 2014)
  • TABLE 6 CBER-LICENSED SCREENING TESTS FOR HEPATITIS C (LAST UPDATED JULY 2014)
  • TABLE 7 CBER-LICENSED SCREENING TESTS FOR HTLV-I AND HTLV-II (LAST UPDATED JULY 2014)
  • TABLE 8 CBER-LICENSED SCREENING TESTS FOR CMV (LAST UPDATED JULY 2014)
  • TABLE 9 CBER LICENSED SCREENING TESTS FOR WEST NILE (LAST UPDATED JULY 2014)
  • TABLE 10 CBER-APPROVED MANUFACTURERS FOR SYPHILIS TESTS (LAST UPDATED JULY 2014)
  • TABLE 11 CBER-LICENSED SCREENING TESTS FOR T. CRUZI (LAST UPDATED JULY 2014)
  • TABLE 12 CBER-APPROVED MANUFACTURERS FOR CHLAMYDIA SCREENING TESTS (LAST UPDATED JULY 2014)
  • TABLE 13 CBER-LICENSED SCREENING TESTS FOR GONORRHEA (LAST UPDATED JULY 2014)
  • TABLE 14 FDA-REGISTERED BLOOD ESTABLISHMENTS BY STATE' AND POSSESSION
  • TABLE 15 ESTIMATED WORLD POPULATION ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
  • TABLE 16 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)
  • TABLE 17 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
  • TABLE 18 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY GENDER, 2000 AND 2020 (YEARS)
  • TABLE 19 EUROPE POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
  • TABLE 20 ASIA-PACIFIC POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
  • TABLE 21 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013 (YEARS)
  • TABLE 22 TESTS ROUTINELY PERFORMED ON BLOOD DONATIONS
  • TABLE 23 BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS
  • TABLE 24 SELECTED USES OF FFP
  • TABLE 25 LISTING OF BLOOD PRODUCTS FOR THERAPEUTIC USE
  • TABLE 26 FACTORS TO REDUCE RISKS OF TRANSFUSION-ASSOCIATED DISEASES
  • TABLE 27 TRANSFUSION-RELATED FATALITIES BY COMPLICATION, FY2008 -FY2012
  • TABLE 28 FATALITIES NOT RELATED TO TRANSFUSION OR TRANSFUSION NOT RULED OUT, FY2008-FY2012
  • TABLE 29 POST-DONATION "NOT RULED OUT" FATALITY REPORTS BY DONATED PRODUCT, FY2008-FY2012
  • TABLE 30 FEDERAL ORGANIZATIONS RESPONSIBLE FOR U.S. BLOOD SAFETY
  • TABLE 31 FDA AUTHORITY IN REGULATING BLOOD BANKING AND BLOOD PRODUCTS
  • TABLE 32 MAJOR AREAS OF CONCERN FOR INSPECTING BLOOD FACILITIES
  • TABLE 33 U.S. COST OF BLOOD COMPONENTS, ESTIMATED, THROUGH 2014 ($)
  • TABLE 34 U.S. BLOOD TRANSFUSION AND RELATED SERVICES CODES
  • TABLE 35 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, THROUGH 2019* (MILLION UNITS/PINTS)
  • TABLE 36 ESTIMATED AND PROJECTED GLOBAL PLASMA COLLECTIONS AND VALUES, THROUGH 2019 ($ BILLIONS, MILLIONS ML)
  • TABLE 37 GLOBAL SALES OF PLASMA THERAPEUTICS*, THROUGH 2019 ($ MILLIONS)
  • TABLE 38 GLOBAL MARKET SIZE PLASMA THERAPEUTIC DERIVATIVES BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 39 ALBUMIN AND PLASMA PROTEIN FRACTION (PPF) PRODUCTS (%)
  • TABLE 40 GLOBAL MARKET FOR ALBUMIN AND PPF, THROUGH 2019 ($ MILLIONS)
  • TABLE 41 GLOBAL MARKET FOR ALBUMIN AND PPF BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 42 EXAMPLES OF COMMON BLOOD CLOTTING FACTORS
  • TABLE 43 GLOBAL AND U.S. HEMOPHILIA STATISTICS
  • TABLE 44 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, THROUGH 2019 ($ MILLIONS)
  • TABLE 45 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 46 APPROVED FACTOR VIII PRODUCTS
  • TABLE 47 GLOBAL MARKET SHARE FACTOR VIII COMPANIES, 2014 (%/$ MILLIONS)
  • TABLE 48 APPROVED FACTOR IX PRODUCTS
  • TABLE 49 GLOBAL MARKET SHARE FACTOR IX COMPANIES, 2014 (%/$ MILLIONS)
  • TABLE 50 APPROVED FACTOR VII PRODUCTS
  • TABLE 51 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2014 (%/$ MILLIONS)
  • TABLE 52 APPROVED FACTOR XIII PRODUCTS
  • TABLE 53 APPROVED PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS
  • TABLE 54 SELECTED CONDITIONS TREATED BY IVIG
  • TABLE 55 APPROVED IMMUNOGLOBULINS
  • TABLE 56 APPROVED HYPERIMMUNE IMMUNOGLOBULINS
  • TABLE 57 GLOBAL MARKET FOR IMMUNOGLOBULINS, THROUGH 2019 ($ MILLIONS)
  • TABLE 58 GLOBAL MARKET FOR IMMUNOGLOBULINS BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 59 GLOBAL MARKET SHARE OF IMMUNOGLOBULIN COMPANIES, 2014
  • TABLE 60 APPROVED FIBRIN SEALANTS AND FIBRIN PRODUCTS
  • TABLE 61 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN, THROUGH 2019 ($ MILLIONS)
  • TABLE 62 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 63 GLOBAL MARKET SHARE OF FIBRIN SEALANTS AND THROMBIN PRODUCT COMPANIES, 2014 (%/$ MILLIONS)
  • TABLE 64 APPROVED ANTITHROMBIN PRODUCTS
  • TABLE 65 GLOBAL MARKET FOR ANTITHROMBIN, THROUGH 2019 ($ MILLIONS)
  • TABLE 66 GLOBAL MARKET FOR ANTITHROMBIN BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 67 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 68 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 69 SELECTED PCR DONOR SCREENING TESTS
  • TABLE 70 SELECTED NAT DONOR SCREENING TESTS
  • TABLE 71 SELECTED IMMUNOASSAY DONOR SCREENING TESTS
  • TABLE 72 GLOBAL BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TESTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 73 BLOOD GROUP AND RH TYPE AND COMPATIBLE BLOOD FOR TRANSFUSION
  • TABLE 74 GLOBAL BLOOD TYPING MARKET: INSTRUMENTS AND SUPPLIES BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 75 GLOBAL SALES OF BLOOD COLLECTION AND PROCESSING EQUIPMENT AND DISPOSABLES, THROUGH 2019 ($ MILLIONS)
  • TABLE 76 GLOBAL MARKET FOR BLOOD AND PLASMA COLLECTION/ TRANSFUSION PRODUCTS, THROUGH 2019 ($ MILLIONS)
  • TABLE 77 GLOBAL MARKET FOR BLOOD COLLECTION PRODUCTS BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 78 GLOBAL MARKET FOR TRANSFUSION PRODUCTS BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 79 CLINICAL TRIAL: ALBUMIN IN ALZHEIMER'S TREATMENT
  • TABLE 80 DOG AND CAT BLOOD TYPES AND DESCRIPTIONS
  • TABLE 81 REGIONAL VETERINARY BLOOD BANKS
  • TABLE 82 RECENTLY ISSUED PATENTS
  • TABLE 83 PATENTS BY COUNTRY OF ORIGIN
  • TABLE 84 RECENT PATENTS BY ASSIGNEE
  • TABLE 85 ABBOTT'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 86 ASTRAZENECA'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 87 BAXTER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 88 BAYER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 89 BIO-RAD'S SALES HISTORY, 2012-2014* ($ THOUSANDS)
  • TABLE 90 CSL LIMITED'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 91 GRIFOLS' SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 92 HAEMONETICS' SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 93 HOLOGIC'S SALES HISTORY, 2012-2014 ($ MILLIONS)
  • TABLE 94 LFB GROUP'S SALES HISTORY, 2012-2013 ($ MILLIONS)
  • TABLE 95 NOVO NORDISK'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 96 OCTAPHARMA'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 97 PFIZER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 98 ROCHE'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • TABLE 99 SANOFI'S SALES HISTORY, 2012-2014* ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL SALES OF BLOOD PRODUCTS, 2011-2019 ($ MILLIONS)
  • FIGURE 1 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)
  • FIGURE 2 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)
  • FIGURE 3 U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
  • FIGURE 4 ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY GENDER, 2000-2020 (YEARS)
  • FIGURE 5 EUROPE POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
  • FIGURE 6 ASIA-PACIFIC POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2050 (THOUSANDS)
  • FIGURE 7 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013 (YEARS)
  • FIGURE 8 VARIABLES INFLUENCING THE DYNAMICS OF DEMAND FOR BLOOD FOR TRANSFUSION
  • FIGURE 9 BLOOD MARKET COST AND PRICING ANALYSIS
  • FIGURE 10 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, 2007-2019 (MILLION UNITS/PINTS)
  • FIGURE 11 ESTIMATED AND PROJECTED GLOBAL PLASMA COLLECTIONS MARKET VALUE, 2013-2019 ($ BILLIONS)
  • FIGURE 12 GLOBAL SALES OF PLASMA THERAPEUTICS*, 2011-2019 ($ MILLIONS)
  • FIGURE 13 MARKET SHARE FOR PLASMA THERAPEUTIC SALES BY REGION, 2014 (%)
  • FIGURE 14 GLOBAL MARKET SIZE PLASMA THERAPEUTIC DERIVATIVES BY TYPE, 2011-2019 ($ MILLIONS)
  • FIGURE 15 GLOBAL MARKET FOR ALBUMIN AND PPF, 2011-2019 ($ MILLIONS)
  • FIGURE 16 GLOBAL MARKET FOR ALBUMIN AND PPF BY REGION, 2011-2019 ($ MILLIONS)
  • FIGURE 17 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, 2011-2019 ($ MILLIONS)
  • FIGURE 18 GLOBAL MARKET SHARE OF CLOTTING FACTOR SALES BY HUMAN AND RECOMBINANT PRODUCTS, 2014 (%)
  • FIGURE 19 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS BY REGION, 2011-2019 ($ MILLIONS)
  • FIGURE 20 GLOBAL MARKET SHARE OF FACTOR VIII COMPANIES, 2014 (%)
  • FIGURE 21 GLOBAL MARKET SHARE OF FACTOR VIII SALES BY HUMAN AND RECOMBINANT PRODUCTS, 2014 (%)
  • FIGURE 22 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2014 (%)
  • FIGURE 23 GLOBAL MARKET SHARE OF FACTOR IX SALES BY HUMAN AND RECOMBINANT PRODUCTS, 2014 (%)
  • FIGURE 24 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2014 (%)
  • FIGURE 25 GLOBAL MARKET FOR IMMUNOGLOBULINS, 2011-2019 ($ MILLIONS)
  • FIGURE 26 GLOBAL MARKET FOR IMMUNOGLOBULINS BY REGION, 2011-2019 ($ MILLIONS)
  • FIGURE 27 GLOBAL MARKET SHARE OF IMMUNOGLOBULIN COMPANIES, 2014 (%)
  • FIGURE 28 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN, 2011- 2019 ($ MILLIONS)
  • FIGURE 29 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN BY REGION, 2011-2019 ($ MILLIONS)
  • FIGURE 30 GLOBAL MARKET SHARE OF FIBRIN SEALANTS AND THROMBIN PRODUCT COMPANIES, 2014 (%)
  • FIGURE 31 GLOBAL MARKET FOR ANTITHROMBIN, 2011-2019 ($ MILLIONS)
  • FIGURE 32 GLOBAL MARKET FOR ANTITHROMBIN BY REGION, 2011-2019 ($ MILLIONS)
  • FIGURE 33 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS BY REGION, 2011-2019 ($ MILLIONS)
  • FIGURE 34 MARKET SHARE FOR BLOOD TYPING AND SCREENING PRODUCT SALES BY REGION, 2014 (%)
  • FIGURE 35 GLOBAL MARKET FOR BLOOD TYPING AND SCREENING PRODUCTS, 2011-2019 ($ MILLIONS)
  • FIGURE 36 GLOBAL BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TEST, 2011- 2019 ($ MILLIONS)
  • FIGURE 37 GLOBAL BLOOD TYPING MARKET: INSTRUMENTS AND SUPPLIES BY TYPE, 2011-2019 ($ MILLIONS)
  • FIGURE 38 GLOBAL SALES OF BLOOD COLLECTION AND PROCESSING EQUIPMENT AND DISPOSABLES, 2011-2019 ($ MILLIONS)
  • FIGURE 39 MARKET SHARE FOR BLOOD COLLECTION AND PROCESSING EQUIPMENT AND DISPOSABLE SALES BY REGION, 2014 (%)
  • FIGURE 40 GLOBAL MARKET FOR BLOOD AND PLASMA COLLECTION/ TRANSFUSION PRODUCTS, 2011-2019 ($ MILLIONS)
  • FIGURE 41 GLOBAL MARKET FOR COLLECTION PRODUCTS BY TYPE, 2011-2019 ($ MILLIONS)
  • FIGURE 42 GLOBAL MARKET FOR TRANSFUSION PRODUCTS BY TYPE, 2011-2019 ($ MILLIONS)
  • FIGURE 43 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS
  • FIGURE 44 ABBOTT'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 45 ASTRAZENECA'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 46 BAXTER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 47 BAYER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 48 BIO-RAD'S SALES HISTORY, 2012-2014* ($ THOUSANDS)
  • FIGURE 49 CSL LIMITED'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 50 GRIFOLS' SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 51 HAEMONETICS' SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 52 HOLOGIC'S SALES HISTORY, 2012-2014 ($ MILLIONS)
  • FIGURE 53 LFB GROUP'S SALES HISTORY, 2012-2013 ($ MILLIONS)
  • FIGURE 54 NOVO NORDISK'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 55 OCTAPHARMA'S SALES HISTORY 2012-2014* ($ MILLIONS)
  • FIGURE 56 PFIZER'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 57 ROCHE'S SALES HISTORY, 2012-2014* ($ MILLIONS)
  • FIGURE 58 SANOFI'S SALES HISTORY, 2012-2014* ($ MILLIONS)
Back to Top